Invokana Lawsuit Plaintiffs See Adverse Event Reports Linking Diabetic Ketoacidosis Side Effects To Drug

February 29, 2016 – – TheProductLawyers.com reports on news which appears to link new-generation, type-2 diabetes drug Invokana to a potential increased risk for the development of diabetic ketoacidosis; even more than other types of SGLT2 inhibitor class drugs, in fact, according to clinical trials on the drug.

For those taking Invokana, medical experts are actively working to get more information out to the public, which they believe could help more effectively manage diabetic ketoacidosis risks, a dangerous and potentially fatal health condition in which the blood contains too much toxic acid. This information was reviewed in a recent article which was published in Diabetes Care by the American Heart Association (AHA).

In the Diabetes Care article, authors Dr. Julio Rosenstock and Elle Ferrannini recommend that the responsibility of lowering the risk of diabetic ketoacidosis should start with medical professionals, who should work to carefully evaluate patients who may have pre-existing factors which put them at increased risk of developing the condition. They recommend that patients who do have risk factors be closely monitored for metabolic changes on a regular basis. Additionally, they indicate that risk factors which can cause the development of diabetic ketoacidosis include: patients who have recently been ill, patients who have lowered food and liquid intake, patients with a history of alcohol use, patients with latent autoimmune diabetes, and those with long-standing diabetes with B-cell insufficiency, among other factors.

The researchers also indicate in their report that clinical trials done on the drug, as well as other similar SGLT2 drugs, showed indications that the development of diabetic ketoacidosis was substantially elevated in patients taking Invokana while those using other similar drugs did not experience this. The U.S. Food and Drug Administration (FDA) approved the drug in 2013, but has since noted that they have received multiple adverse event reports which also highlight the development of diabetic ketoacidosis in patients. Additionally, European health officials also recently announced that 101 cases of diabetic ketoacidosis have been reported worldwide at this time in patients.

Diabetic ketoacidosis is a serious and potentially fatal medical condition which can develop in less than 24 hours and become substantially more dangerous if left untreated. Patients suffering from this disorder generally need hospitalization, and, if they go untreated or are undiagnosed, they can slip into a coma or die.

The attorneys at Banville Law sponsor Invokana online resource page TheProductLawyers.com, and are also currently working to assist anyone who took Invokana or other SGLT2 inhibitor drugs and who have suffered from medical conditions which they believe occurred because of these drugs. These patients may be entitled to substantial compensation. To help those deserving to seek justice, the attorneys at Banville Law are offering complimentary legal consultations for affected parties at this time.

To request more information, or to ask questions, contact the attorneys at Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008417